Pharma Focus Asia

Kangen Pharmaceuticals Co., Ltd. Announces Acquisition Of KC Specialty Therapeutics.

Thursday, December 14, 2017

Kangen Pharmaceuticals and KC Specialty Therapeutics announced that Kangen has reached an agreement with KCST and agreed to acquire the assets of KCST. Kangen intends to retain operations in Kansas City, Kansas, USA, with expansions in Japan and the US.

"This is a significant milestone for both Kangen and KCST. This acquisition provides Kangen with a unique opportunity for growth in two major markets – the US and Japan," said Mr. Norihiro Hirota, Chairperson and President of Kangen.

KCST has an existing portfolio of products focused on niche indications, and orphan drug designations.  This acquisition also creates for Kangen an expanded network of affiliates and alliances in Asia and Europe, where Kangen will further expand strategic business alliances and portfolio of branded pharmaceuticals.

Diana Wood, CEO of KCST added, "This acquisition brings together complementary strengths of Kangen and KCST and also enhances our strategic position and value with our partners in Japan." Diana Wood will take on the additional role of the President of Kangen, while Mr. Hirota will retain the chairperson position.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024